SPOP and prostate cancer: Resistance to BET inhibitors in SPOP-mutant prostate cancer can be overcome by combination with AKT inhibitors and further supports the evaluation of SPOP mutations as biomarkers to guide BET inhibitor-directed therapy in prostate cancer patients (282).